AbCellera Reports Q3 2026 Business Results

AbCellera Biologics reported Q3 2026 revenue of $10.6 million, above the FactSet consensus estimate of $8.4 million. Its loss narrowed to $0.13 per share, compared with the estimated loss of $0.17 per share, for the quarter ended September 30, 2026.